A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma

Pheochromocytoma Clinical Trial

— Spencer  

Official title:

A Phase 1/2 Trial of a Novel Therapeutic Vaccine (EO2401) in Combination With Immune Check Point Blockade, for Treatment of Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04187404
• Other study ID #: EOADR1-19
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• Start date: July 23, 2020
• Est. completion date: November 30, 2025

Study information

• Verified date: November 2023
• Source: Enterome
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, Phase 1/2, First-In-Human study to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma.

Description:

EO2401 is an innovative cancer peptide therapeutic vaccine based on the homologies between Tumor Associated Antigens and microbiome-derived peptides that will be administered in combination with nivolumab to generate preliminary safety and efficacy data in patients with Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 70
• Est. completion date: November 30, 2025
• Est. primary completion date: May 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Main Inclusion Criteria:

1. For inclusion in Cohort 1 patients should have adrenocortical carcinoma(ACC), or malignant pheochromocytoma/paraganglioma (MPP), as defined below for Cohorts 2A and 3A.

2. For inclusion in Cohorts 2A and 2B patients should have histologically confirmed (at primary diagnosis) unresectable locally advanced or metastatic adrenocortical carcinoma.

3. For inclusion in Cohorts 3A and 3B patients should have histologically confirmed (at primary diagnosis) unresectable malignant (defined as metastatic disease, i.e. presence of chromaffin tissue in non-chromaffin organs) pheochromocytoma/paraganglioma, and RECIST defined progression should have been documented during a maximum of an 18-months period.

4. Patients with an age = 18 years old.

5. Patients who are human leukocyte antigen (HLA)-A2 positive.

6. Patients with an Eastern Cooperative Oncology Group (ECOG) performance status = 1.

7. Patients with a life expectancy > 4 months as judged by their treating physician.

8. Patients with at least one measurable lesion according to RECIST 1.1.

9. Males or non-pregnant, non-lactating, females.

10. Patients willing and able to comply with the scheduled visits, treatment plan, laboratory tests, and other study procedures indicated in the protocol.

11. Patients having received the information sheet and who have provided written informed consent prior to any study-related procedures.

Main Exclusion Criteria:

1. Patients treated with dexamethasone > 2 mg/day or equivalent (i.e. 13 mg/day of prednisone, or 53 mg/day of hydrocortisone) within 14 days before the first EO2401 administration, unless required to treat an adverse event.

2. Patients with prior treatment with immune check-point inhibitors

3. Patients with prior exposure to EO2401.

4. Patients treated with immunotherapy (meaning immunostimulatory or immunosuppressive therapy; beside excluded, or allowed, compounds per other inclusion/exclusion criteria specifications), radionuclide therapy, radiotherapy, cytoreductive therapy, or received treatment with any other investigational agent within 28 days before the first EO2401 administration.

5. Patients with an initial diagnosis of ACC less than 9 months from start of screening part 2.

6. Patients with ACC and any individual lesion according to RECIST 1.1 having a maximum diameter of more than 125 mm; irrespective if the lesion is proposed as a target lesion, or not, according to RECIST 1.1.

7. Patients with ACC with more than three organs involved by disease, combined with unresectable primary tumor.

8. Patients with ACC and uncontrolled hormonal secretion (according to the judgement of the treating physician).

9. Patients with MPP and uncontrolled blood pressure (according to the judgement of the treating physician).

10. Patients with abnormal laboratory values.

11. Patients with persistent Grade 3 or 4 toxicities.

12. Uncontrolled central nervous system (CNS) metastasis.

13. Other malignancy or prior malignancy with a disease-free interval of less than 3 years

14. Patients with clinically significant disease.

15. Patients with suspected autoimmune or active autoimmune disorder or known history of an autoimmune neurologic condition (e.g. Guillain-Barré syndrome).

16. Patients with history of solid organ transplantation or hematopoietic stem cell transplantation.

17. Patients with history or known presence of tuberculosis.

18. Pregnant and breastfeeding patients.

19. Patients with history or presence of human immunodeficiency virus and/or potentially active hepatitis B virus/hepatitis C virus infection.

20. Patients who have received live or attenuated vaccine therapy used for prevention of infectious diseases including seasonal (influenza) vaccinations within 4 weeks of the first dose of study drug.

21. Patients with a history of hypersensitivity to any excipient present in the pharmaceutical forms of the study treatments.

22. Patients treated with herbal remedies with immunostimulating properties or known to potentially interfere with major organ function.

23. Patients with known ongoing drug and alcohol abuse.

24. Patients with known or underlying medical or psychiatric condition that, in the Investigator's opinion, would make the administration of study drug hazardous to the patient or obscure the interpretation of toxicity determination or AEs.

25. Patients deprived of their liberty, under protective custody, or guardship.

Related Conditions & MeSH terms

• Adrenocortical Carcinoma
• Carcinoma
• Paraganglioma
• Pheochromocytoma

Intervention

Biological:
• EO2401
Multiple dose of EO2401
• Nivolumab
Multiple dose of nivolumab

Locations

Country	Name	City	State
Denmark	Rigshospitalet	Copenhagen
France	Chu Lille	Lille
France	Centre Léon Bérard	Lyon
France	Assistance Publique - Hôpitaux de Marseille - Hôpital Nord	Marseille
France	Institut Gustave Roussy	Villejuif
Germany	Lmu Klinikum	München
Germany	Universitätsklinikum Würzburg	Würzburg
Italy	Azienda Ospedaliera Spedali Civili	Brescia
Netherlands	Amsterdam UMC, location VUmc	Amsterdam
Spain	Hospital Universitari Vall d'Hebron	Barcelona
Sweden	Karolinska University Hospital	Stockholm
United States	MD Anderson Cancer Center	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Enterome

Countries where clinical trial is conducted

United States,  Denmark,  France,  Germany,  Italy,  Netherlands,  Spain,  Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adverse events assessment	Incidences of adverse events(AEs), treatment-emergent AEs (TEAEs), Serious Adverse Events ( SAEs), deaths, and laboratory abnormalities using the National Cancer Institute-Common Terminology Criteria for AEs (NCI-CTCAE) v5.0.	Up to 24 months
Secondary	Evaluation of Progression Free Survival at 6 months	Progression Free Survival according to iRECIST criteria defined as the time interval from the date of first study treatment administration to 6 months after	6 months after first treatment date from the last patient enrolled
Secondary	Evaluation of survival	Overall survival, defined as the time interval from the date of first study treatment administration to the date of death due to any cause	From end of treatment to at least 24 months after last patient enrollment
Secondary	Assessment of the immunogenicity	Assessment of the immunogenicity of the 4 components that compose EO2401 Immunogenicity will be assessed by Interferon-? ELISpot	Up to 24 months